NanoBRET TE Intracellular Kinase Assay

407 validated kinase targets, each benchmarked with a reference inhibitor. Targets are available individually or across nine panels, including our 192-kinase K192 primary screening panel and focused mutant panels for ABL1, FLT3, KIT, MET, PIK3CA, PKC, and TEK.

K192 screens 192 kinases at a single concentration in duplicate, giving broad selectivity coverage across the kinome for early-stage triage. The focused mutant panels (ABL1, FLT3, KIT, MET, PIK3CA, TEK) run in 10-dose IC50 duplicate against a specific target family, suited for resistance-mutation profiling once a program has a defined target of interest.

Yes. Submit a compound-specific tracer or probe for evaluation and our team will assess feasibility for adding it to your project.

Residence time is how long a compound stays bound to its target after an unbound drug is removed. Two compounds with similar potency can have very different residence times, and longer residence time often correlates with more durable pharmacological effect in cells. Residence time analysis is available on request for any listed target.

Single targets and focused mutant panels typically report in 2 to 3 weeks; the CDK Panel (20 targets) and K192 Panel (192 targets) typically complete in around 4 weeks. Expedited scheduling is available on request. New or custom targets require approximately 2 weeks for assay establishment before compound testing begins.

Requests are triaged through our Malvern, PA, USA facility by default. Clients requiring EU-based execution can arrange technology transfer to our Freiburg, Germany site.

Typically 50 to 100 uL of a 10 to 50 mM DMSO stock, or 2 to 3 mg of solid material. See our FAQ page for full compound preparation and shipping guidance.

NanoBRET assays can be used to evaluate allosteric kinase inhibitors. However, assay sensitivity and suitability can vary depending on tracer selection and vector design. Because NanoBRET tracers are typically developed from Type I ATP‑competitive inhibitors, their responsiveness to non‑ATP‑site binders depends on whether allosteric binding induces a conformational change that decreases ATP‑site tracer affinity. Under those conditions, NanoBRET can effectively assess allosteric kinase inhibitors, including Type II, III, and IV inhibitors.